UOC
LRMR icon

UBS O'Connor’s Larimar Therapeutics LRMR Stock Holding History

UBS O'Connor’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-307,198
Closed -$888K – 381
2025
Q2 		$888K Buy
307,198
+127,171
+71% +$294K 0.02% 236
2025
Q1 		$387K Sell
180,027
-8,516
-5% -$26.9K 0.01% 230
2024
Q4 		$730K Sell
188,543
-14,240
-7% -$94K 0.02% 256
2024
Q3 		$1.33M Sell
202,783
-5,000
-2% -$40.2K 0.03% 244
2024
Q2 		$1.51M Buy
207,783
+5,000
+2% +$38.3K 0.04% 235
2024
Q1 		$1.54M Sell
202,783
-117,118
-37% -$913K 0.04% 229
2023
Q4 		$1.46M Sell
319,901
-58,604
-15% -$198K 0.05% 223
2023
Q3 		$1.5M Buy
378,505
+15,000
+4% +$56.7K 0.03% 286
2023
Q2 		$1.14M Buy
363,505
+151,011
+71% +$616K 0.02% 370
2023
Q1 		$963K Buy
+212,494
New +$1.11M 0.02% 409
2015
Q3 		– Sell
-6,683
Closed -$2.78M – 635
2015
Q2 		$2.78M Buy
6,683
+3,350
+101% +$1.4M 0.05% 306
2015
Q1 		$1.58M Buy
+3,333
New +$1.58M 0.03% 327

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

UBS O'Connor's LRMR Position: Q3 2025 in Review

UBS O'Connor sold out of Larimar Therapeutics (LRMR) in Q3 2025, closing a stake of 307,198 shares — an estimated $888K sold.

UBS O'Connor first reported a position in LRMR in Q1 2015 and held it in 12 quarters. The position peaked at $2.78M in Q2 2015. 136 funds tracked by Wall St. Rank hold LRMR as of Q3 2025.

  • UBS O'Connor reported no remaining Larimar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 307,198 Larimar Therapeutics shares in Q3 2025, an estimated $888K.
  • UBS O'Connor first reported a position in Larimar Therapeutics in Q1 2015 and held it in 12 quarters.
  • UBS O'Connor's Larimar Therapeutics position peaked at $2.78M in Q2 2015.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.